In 2025, West Pharmaceutical Services completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
West Pharmaceutical Services has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 33,767a | 31,431b | 31,017c | |
Total Scope 2 | ||||
Market-Based | 64,002a | 70,027b | N/A | |
Location-Based | 105,424a | N/A | N/A | |
Unspecified Calculation Method | N/A | N/A | 73,173c | |
Total Scope 3 | 538,943b | 513,876b | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 10.9844a | 10.8637b | 10.515c |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of West Pharmaceutical Services amounted to 139,191 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of West Pharmaceutical Services increased by 37.19%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab
In 2025, the total Scope 1 emissions of West Pharmaceutical Services were 33,767 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, West Pharmaceutical Services's Scope 1 emissions have increased by 19.48%, reflecting a rising long-term trend in Scope 1 emissions over time.ad
Compared to the previous year (2024), West Pharmaceutical Services's Scope 1 emissions increased by 7.43%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.ab
In 2025, West Pharmaceutical Services reported Scope 2 greenhouse gas (GHG) emissions of 64,002 tCO₂e using the market-based method and 105,424 tCO₂e using the location-based method.a
In 2025, West Pharmaceutical Services reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, West Pharmaceutical Services reported 538,943 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.b
The 2025 disclosure of West Pharmaceutical Services includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.b
In 2025, West Pharmaceutical Services reported total Scope 3 emissions of 538,943 metric tons of CO₂ equivalent (tCO₂e).b
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.b
Compared to the previous year (2024), West Pharmaceutical Services's Scope 3 emissions remained relatively stable, indicating that West Pharmaceutical Services's emissions have plateaued with no significant change in its value chain footprint.b
In 2025, West Pharmaceutical Services reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.b
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to West Pharmaceutical Services's Scope 3 emissions were:b
In 2025, West Pharmaceutical Services reported Scope 1 greenhouse gas (GHG) emissions of 33,767 tCO₂e and total revenues of USD 3,074 millions. This translates into an emissions intensity of 10.98 tCO₂e per millions USD.a
In 2025, West Pharmaceutical Services reported a Scope 1 emissions intensity of 10.98 tCO₂e per millions USD. Compared to the peer group median of 4.59, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, West Pharmaceutical Services ranked 21 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places West Pharmaceutical Services among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2025, West Pharmaceutical Services reported a total carbon footprint of 678,134 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 10.21% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to West Pharmaceutical Services's total carbon footprint was Scope 3 emissions, accounting for 79.47% of the company's total carbon footprint, followed by Scope 2 emissions at 15.55%.ab